Related Experiment Video
Updated: Feb 22, 2026
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
Evaluation of Helicobacter pylori infection and clinical features in multiple sclerosis patients coexisting with
Maryam Aghaei1, Shahrzad Aghaei2, Zabihollah Shahmoradi3
1Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Background:
Multiple Autoimmune Syndrome (MAS) involves at least three distinct autoimmune diseases. MAS' exact cause is unknown, however, genetic, immunologic, environmental, and infectious factors like Helicobacter pylori (H.pylori) are involved in its pathophysiology. Hence, in the current study, we described the demographic, and clinical characteristics of Multiple Sclerosis (MS) patients coexisting with vitiligo. Furthermore, we investigated the relationship between H. pylori eradication and patients' clinical improvement.
Materials And Methods:
In this case-series study, eight female MS patients with clinically confirmed vitiligo were assessed for demographic and clinical characteristics via questionnaires and medical records. H. pylori infection also was evaluated using ELISA and stool antigen (HpSag) tests, and positive cases received eradication therapy.
Results:
The mean onset ages for MS and vitiligo were 23.12 ± 5.27 and 26.75 ± 4.97 years, with disease durations of 10.4 and 6.8 years, respectively. Six patients (75%) had an active vitiligo, and only one had active MS. Family history of MS and vitiligo was observed in 37.5% and 50% of patients, while 87.5% had other autoimmune diseases in their families. The mean H.pylori IgG and IgM levels were 15.58 ± 13.63 and 0.43 ± 0.31, respectively and H. pylori infection was detected in 25% of patients by either serology or stool antigen test, and no active vitiligo was observed post-eradication.
Conclusion:
Since, our findings showed a potential association between H. pylori infection and the pathophysiology of vitiligo, eradication therapy may be used as a complementary approach alongside standard vitiligo treatments or even MS in MAS patients.
Related Concept Videos
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...